Products

We are committed to the development of human monoclonal antibodies as new treatments for important human diseases to improve patients' lives. The effectiveness of our world-class antibody technologies and capabilities is demonstrated by the Cambridge site's product pipeline. HUMIRA^® is already approved and marketed in over 50 countries worldwide and 10 further human monoclonal antibodies originating from MedImmune Cambridge (formerly CAT) are in clinical trials.

To see individual profiles for Cambridge-derived proprietary, collaborative and licensees' products, please click on the links below.

Three further products developed by MedImmune's patent licensees are also in clinical trials, namely MT201, IMC-11F8 and IMC-1121B. Please see Patent Licensing for further information.

Featured project from MedImmune in the USA

Our colleagues in the United States have developed three marketed products and have an advancing pipeline of promising candidates, all designed to treat or prevent a number of debilitating or life-threatening diseases. Here we feature one program that has recently advanced to Phase II clinical trials:

MEDI-528, anti-IL-9 monoclonal antibody for asthma